How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review Review uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow Neoplasms
  • Bone Neoplasms
  • Brain Neoplasms
  • Neuroectodermal Tumors, Primitive
  • Sarcoma, Ewing

abstract

  • The MSKCC experience and findings reported in the literature suggest that dose-intensive use of the chemotherapy agents with established activity against ES/PNET is reaching its efficacy and toxicity limits. A major impact on prognosis awaits the development of entirely novel therapies.

publication date

  • February 2001

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 11157041

Additional Document Info

start page

  • 870

end page

  • 80

volume

  • 19

number

  • 3